RS50676B - Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja - Google Patents

Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja

Info

Publication number
RS50676B
RS50676B YUP-677/03A YUP67703A RS50676B RS 50676 B RS50676 B RS 50676B YU P67703 A YUP67703 A YU P67703A RS 50676 B RS50676 B RS 50676B
Authority
RS
Serbia
Prior art keywords
tremors
tremor
group
formula
movement disorders
Prior art date
Application number
YUP-677/03A
Other languages
English (en)
Serbian (sr)
Inventor
Boyu Zhao
Carlos Plata-Salman
Roy Twyman
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of YU67703A publication Critical patent/YU67703A/sh
Publication of RS50676B publication Critical patent/RS50676B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YUP-677/03A 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja RS50676B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168301P 2001-02-27 2001-02-27
US10/081,501 US6589985B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders

Publications (2)

Publication Number Publication Date
YU67703A YU67703A (sh) 2006-08-17
RS50676B true RS50676B (sr) 2010-06-30

Family

ID=26765643

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-677/03A RS50676B (sr) 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja

Country Status (27)

Country Link
US (1) US6589985B2 (cs)
EP (1) EP1411917B1 (cs)
JP (1) JP2004527492A (cs)
KR (1) KR100858232B1 (cs)
CN (1) CN1262272C (cs)
AR (1) AR033426A1 (cs)
AT (1) ATE369130T1 (cs)
AU (1) AU2002247204B2 (cs)
BR (1) BR0207831A (cs)
CA (1) CA2439478C (cs)
CY (1) CY1106924T1 (cs)
CZ (1) CZ20032299A3 (cs)
DE (1) DE60221670T2 (cs)
DK (1) DK1411917T3 (cs)
ES (1) ES2291454T3 (cs)
HU (1) HUP0303344A3 (cs)
IL (2) IL157592A0 (cs)
MX (1) MXPA03007719A (cs)
MY (1) MY157373A (cs)
NO (1) NO20033803L (cs)
NZ (1) NZ551954A (cs)
PL (1) PL364679A1 (cs)
PT (1) PT1411917E (cs)
RS (1) RS50676B (cs)
RU (1) RU2294739C2 (cs)
TW (1) TWI331524B (cs)
WO (1) WO2002067926A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007822A2 (en) * 2000-07-21 2002-01-31 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
IL157591A0 (en) * 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
PL368164A1 (en) 2001-07-16 2005-03-21 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
AU2006254899B2 (en) * 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
CA2616721C (en) * 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
CA2667909A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
JP6131341B2 (ja) 2013-03-12 2017-05-17 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物及びこれを含む精神疾患の予防又は治療用組成物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄａｎｄａｃｏｍｐｏｓｉｔｉｏｎｆｏｒｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇａｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒｃｏｍｐｒｉｓｉｎｇｔｈｅｓａｍｅ｝
US10351519B2 (en) * 2016-02-29 2019-07-16 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
US11033531B2 (en) * 2016-12-14 2021-06-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
CA3191072A1 (en) * 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
CA2439478A1 (en) 2002-09-06
MXPA03007719A (es) 2004-11-12
CN1505508A (zh) 2004-06-16
DE60221670T2 (de) 2008-04-30
MY157373A (en) 2016-06-15
KR100858232B1 (ko) 2008-09-12
WO2002067926A1 (en) 2002-09-06
BR0207831A (pt) 2004-06-22
TWI331524B (en) 2010-10-11
NO20033803D0 (no) 2003-08-26
HK1067305A1 (en) 2005-04-08
AR033426A1 (es) 2003-12-17
AU2002247204B2 (en) 2006-08-24
PL364679A1 (en) 2004-12-13
HUP0303344A2 (hu) 2004-01-28
US20020151585A1 (en) 2002-10-17
RU2294739C2 (ru) 2007-03-10
CN1262272C (zh) 2006-07-05
CA2439478C (en) 2010-05-18
RU2003128985A (ru) 2005-03-10
US6589985B2 (en) 2003-07-08
IL157592A (en) 2009-12-24
JP2004527492A (ja) 2004-09-09
CZ20032299A3 (cs) 2004-08-18
NO20033803L (no) 2003-10-10
PT1411917E (pt) 2007-09-17
KR20030074847A (ko) 2003-09-19
YU67703A (sh) 2006-08-17
CY1106924T1 (el) 2012-09-26
DK1411917T3 (da) 2007-09-24
IL157592A0 (en) 2004-03-28
EP1411917A1 (en) 2004-04-28
NZ551954A (en) 2008-07-31
DE60221670D1 (de) 2007-09-20
ES2291454T3 (es) 2008-03-01
EP1411917B1 (en) 2007-08-08
ATE369130T1 (de) 2007-08-15
HUP0303344A3 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
EP1411917B1 (en) Carbamate compounds for use in preventing or treating movement disorders
HK1224209A1 (en) Huperzine for use in treating seizure, pain, orthostatic hypotension or vertigo
AU2002247204A1 (en) Carbamate compounds for use in preventing or treating movement disorders
RU2286147C2 (ru) Карбаматы для применения для предотвращения или лечения биполярного расстройства
RU2300372C2 (ru) Карбаматы для применения для предотвращения или лечения биполярного расстройства
AU2002254015B2 (en) Carbamate compounds for use in the treatment of pain
AU2002306567B2 (en) Carbamate compounds for use in preventing or treating anxiety disorders
AU2002242296B2 (en) Carbamate compounds for use in preventing or treating psychotic disorders
JP4362367B2 (ja) 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物
JP4362368B2 (ja) 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物
HK1067305B (en) Carbamate compounds for use in preventing or treating movement disorders
ZA200401155B (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain.